{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:31:38Z","timestamp":1781058698645,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00520-017-4035-7","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T22:01:17Z","timestamp":1516312877000},"page":"2031-2038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2639-9286","authenticated-orcid":false,"given":"James","family":"Granfortuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaye","family":"Shoffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"DePasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal","family":"Badre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chet","family":"Bohac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cisio","family":"De Oliveira Brandao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"issue":"3 Suppl 2","key":"4035_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2146\/ajhp060601","volume":"64","author":"RN Schwartz","year":"2007","unstructured":"Schwartz RN (2007) Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 64(3 Suppl 2):S5\u201313. \n                    https:\/\/doi.org\/10.2146\/ajhp060601","journal-title":"Am J Health Syst Pharm"},{"issue":"19","key":"4035_CR2","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91(19):1616\u20131634. \n                    https:\/\/doi.org\/10.1093\/jnci\/91.19.1616","journal-title":"J Natl Cancer Inst"},{"key":"4035_CR3","unstructured":"National Comprehensive Cancer Network. NCCN\u00ae clinical practice guidelines in oncology. Cancer- and chemotherapy-induced anemia version 1.2018. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anemia.pdf\n                    \n                   Accessed 8 December 2017"},{"issue":"Suppl 2","key":"4035_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000088282","volume":"69","author":"P Harper","year":"2005","unstructured":"Harper P, Littlewood T (2005) Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 69(Suppl 2):2\u20137. \n                    https:\/\/doi.org\/10.1159\/000088282","journal-title":"Oncology"},{"issue":"33","key":"4035_CR5","doi-asserted-by":"publisher","first-page":"8296","DOI":"10.1200\/JCO.2005.10.167","volume":"23","author":"P Nieboer","year":"2005","unstructured":"Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WT, TenVergert EM, van Tinteren H, de Vries EG (2005) Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol 23(33):8296\u20138304. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.10.167","journal-title":"J Clin Oncol"},{"issue":"19","key":"4035_CR6","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1001\/jama.2016.9185","volume":"316","author":"JL Carson","year":"2016","unstructured":"Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, Peterson N, Ramsey G, Rao SV, Roback JD, Shander A, Tobian AA (2016) Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 316(19):2025\u20132035. \n                    https:\/\/doi.org\/10.1001\/jama.2016.9185","journal-title":"JAMA"},{"issue":"13","key":"4035_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra1612789","volume":"377","author":"JL Carson","year":"2017","unstructured":"Carson JL, Triulzi DJ, Ness PM (2017) Indications for and adverse effects of red-cell transfusion. N Engl J Med 377(13):1261\u20131272. \n                    https:\/\/doi.org\/10.1056\/NEJMra1612789","journal-title":"N Engl J Med"},{"key":"4035_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.03.010","volume":"46","author":"LS Prescott","year":"2016","unstructured":"Prescott LS, Taylor JS, Lopez-Olivo MA, Munsell MF, VonVille HM, Lairson DR, Bodurka DC (2016) How low should we go: a systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology. Cancer Treat Rev 46:1\u20138. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.010","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"4035_CR9","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s00520-016-3078-5","volume":"24","author":"L Xu","year":"2016","unstructured":"Xu L, Xu H, Cannavale K, Sattayapiwat O, Rodriguez R, Page JH, Chao C (2016) Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013. Support Care Cancer 24(7):2989\u20132998. \n                    https:\/\/doi.org\/10.1007\/s00520-016-3078-5","journal-title":"Support Care Cancer"},{"issue":"1\u2013202","key":"4035_CR10","first-page":"iii","volume":"11","author":"J Wilson","year":"2007","unstructured":"Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C (2007) A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11:1\u2013202, iii\u2013iv","journal-title":"Health Technol Assess"},{"key":"4035_CR11","volume":"2","author":"SR Hill","year":"2002","unstructured":"Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland DB, Henderson KM (2002) Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2:CD002042","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"4035_CR12","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1001\/archinte.168.21.2377","volume":"168","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH (2008) Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 168(21):2377\u20132381. \n                    https:\/\/doi.org\/10.1001\/archinte.168.21.2377","journal-title":"Arch Intern Med"},{"issue":"Suppl 3","key":"4035_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1634\/theoncologist.2011-S3-12","volume":"16","author":"D Schrijvers","year":"2011","unstructured":"Schrijvers D (2011) Management of anemia in cancer patients: transfusions. Oncologist 16(Suppl 3):12\u201318. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2011-S3-12","journal-title":"Oncologist"},{"issue":"13","key":"4035_CR14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMp068178","volume":"355","author":"MA Blajchman","year":"2006","unstructured":"Blajchman MA, Vamvakas EC (2006) The continuing risk of transfusion-transmitted infections. N Engl J Med 355(13):1303\u20131305. \n                    https:\/\/doi.org\/10.1056\/NEJMp068178","journal-title":"N Engl J Med"},{"issue":"4","key":"4035_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1758834014534515","volume":"6","author":"PK Corey-Lisle","year":"2014","unstructured":"Corey-Lisle PK, Desrosiers MP, Collins H, De La Orden M, Payne KA, Levache CB, Dumont P (2014) Transfusions and patient burden in chemotherapy-induced anaemia in France. Ther Adv Med Oncol 6(4):146\u2013153. \n                    https:\/\/doi.org\/10.1177\/1758834014534515","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"4035_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/sj.bjc.6600465","volume":"87","author":"JA Glaspy","year":"2002","unstructured":"Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87(3):268\u2013276. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6600465","journal-title":"Br J Cancer"},{"issue":"2","key":"4035_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/00019053-200523020-00009","volume":"23","author":"E Berndt","year":"2005","unstructured":"Berndt E, Crown W, Kallich J, Long S, Song X, Lyman GH (2005) The impact of anaemia and its treatment on employee disability and medical costs. PharmacoEconomics 23(2):183\u2013192. \n                    https:\/\/doi.org\/10.2165\/00019053-200523020-00009","journal-title":"PharmacoEconomics"},{"issue":"2","key":"4035_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1524-4733.2005.03089.x","volume":"8","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Berndt ER, Kallich JD, Erder MH, Crown WH, Long SR, Lee H, Song X, Finkelstein SN (2005) The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 8(2):149\u2013156. \n                    https:\/\/doi.org\/10.1111\/j.1524-4733.2005.03089.x","journal-title":"Value Health"},{"issue":"11","key":"4035_CR19","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","volume":"19","author":"JL Gabrilove","year":"2001","unstructured":"Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19(11):2875\u20132882. \n                    https:\/\/doi.org\/10.1200\/JCO.2001.19.11.2875","journal-title":"J Clin Oncol"},{"key":"4035_CR20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","volume":"122","author":"M Hedenus","year":"2003","unstructured":"Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ, Darbepoetin Alfa 20000161 Study Group (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394\u2013403","journal-title":"Br J Haematol"},{"key":"4035_CR21","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group","year":"2001","unstructured":"Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865\u20132874","journal-title":"J Clin Oncol"},{"issue":"1","key":"4035_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/1471-2407-9-311","volume":"9","author":"J Vansteenkiste","year":"2009","unstructured":"Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B (2009) Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g\/dL versus \u226510 g\/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer 9(1):311. \n                    https:\/\/doi.org\/10.1186\/1471-2407-9-311","journal-title":"BMC Cancer"},{"key":"4035_CR23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","volume":"94","author":"J Vansteenkiste","year":"2002","unstructured":"Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211\u20131220","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"4035_CR24","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2007.15.0748","volume":"26","author":"R Pirker","year":"2008","unstructured":"Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF (2008) Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 26(14):2342\u20132349. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.15.0748","journal-title":"J Clin Oncol"},{"issue":"122\u2013135","key":"4035_CR25","volume":"38","author":"R Pirker","year":"2016","unstructured":"Pirker R, Hedenus M, Vansteenkiste J, Hernandez E, Belton L, Terwey JH (2016) Effectiveness of darbepoetin alfa for chemotherapy-induced anemia when initiated at hemoglobin \u226410 g\/dL. Clin Ther 38:122\u2013135 e126","journal-title":"Clin Ther"},{"issue":"Suppl 7A","key":"4035_CR26","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","volume":"116","author":"K Knight","year":"2004","unstructured":"Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116(Suppl 7A):11S\u201326S","journal-title":"Am J Med"},{"issue":"15","key":"4035_CR27","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","volume":"40","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, Birgeg\u00e5rd G, Bokemeyer C, Gasc\u00f3n P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40(15):2293\u20132306. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2004.06.019","journal-title":"Eur J Cancer"},{"issue":"4","key":"4035_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00520-012-1617-2","volume":"21","author":"R Pirker","year":"2013","unstructured":"Pirker R, Pirolli M, Quigley J, Hulnick S, Legg J, Collins H, Vansteenkiste J (2013) Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent. Support Care Cancer 21(4):987\u2013992. \n                    https:\/\/doi.org\/10.1007\/s00520-012-1617-2","journal-title":"Support Care Cancer"},{"issue":"6","key":"4035_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12094-012-0953-5","volume":"15","author":"JL Steegmann","year":"2013","unstructured":"Steegmann JL, Sanchez Torres JM, Colomer R, Vaz A, Lopez J, Jalon I, Provencio M, Gonzalez-Martin A, Perez M (2013) Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Clin Transl Oncol 15(6):477\u2013483. \n                    https:\/\/doi.org\/10.1007\/s12094-012-0953-5","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"4035_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10147-014-0677-3","volume":"19","author":"A Tanaka","year":"2014","unstructured":"Tanaka A, Yoshino I, Makino S, Katsumata N, Takahashi K, Kuwano H, Maehara Y, Nishiyama M (2014) Questionnaire-based survey on chemotherapy-induced anemia. Int J Clin Oncol 19(3):411\u2013420. \n                    https:\/\/doi.org\/10.1007\/s10147-014-0677-3","journal-title":"Int J Clin Oncol"},{"key":"4035_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/CLEP.S17146","volume":"3","author":"M Yong","year":"2011","unstructured":"Yong M, Riis AH, Fryzek JP, Moller BK, Johnsen SP (2011) Predictors and patterns of red blood cell transfusion use among newly diagnosed cancer patients with chemotherapy-associated anemia in Western Denmark (1998-2003). Clin Epidemiol 3:91\u201399. \n                    https:\/\/doi.org\/10.2147\/CLEP.S17146","journal-title":"Clin Epidemiol"},{"issue":"6","key":"4035_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJM199902113400601","volume":"340","author":"Paul C. H\u00e9bert","year":"1999","unstructured":"Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340(6):409\u2013417. \n                    https:\/\/doi.org\/10.1056\/NEJM199902113400601","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"4035_CR33","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1012452","volume":"365","author":"JL Carson","year":"2011","unstructured":"Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J, FOCUS Investigators (2011) Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 365(26):2453\u20132462. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1012452","journal-title":"N Engl J Med"},{"issue":"14","key":"4035_CR34","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1001\/jama.2010.1446","volume":"304","author":"LA Hajjar","year":"2010","unstructured":"Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, Fukushima J, Kalil Filho R, Sierra DB, Lopes NH, Mauad T, Roquim AC, Sundin MR, Le\u00e3o WC, Almeida JP, Pomerantzeff PM, Dallan LO, Jatene FB, Stolf NA, Auler JO Jr (2010) Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 304(14):1559\u20131567. \n                    https:\/\/doi.org\/10.1001\/jama.2010.1446","journal-title":"JAMA"},{"issue":"15","key":"4035_CR35","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMoa1406617","volume":"371","author":"LB Holst","year":"2014","unstructured":"Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, Johansson PI, Aneman A, Vang ML, Winding R, Nebrich L, Nibro HL, Rasmussen BS, Lauridsen JR, Nielsen JS, Oldner A, Pettil\u00e4 V, Cronhjort MB, Andersen LH, Pedersen UG, Reiter N, Wiis J, White JO, Russell L, Thornberg KJ, Hjortrup PB, M\u00fcller RG, M\u00f8ller MH, Steensen M, Tj\u00e4der I, Kilsand K, Odeberg-Wernerman S, Sj\u00f8b\u00f8 B, Bundgaard H, Thy\u00f8 MA, Lodahl D, Maerkedahl R, Albeck C, Illum D, Kruse M, Winkel P, Perner A, TRISS Trial Group, Scandinavian Critical Care Trials Group (2014) Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 371(15):1381\u20131391. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1406617","journal-title":"N Engl J Med"},{"issue":"964\u2013971","key":"4035_CR36","volume":"165","author":"JL Carson","year":"2013","unstructured":"Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, Srinivas V, Menegus MA, Marroquin OC, Rao SV, Noveck H, Passano E, Hardison RM, Smitherman T, Vagaonescu T, Wimmer NJ, Williams DO (2013) Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 165:964\u2013971 e961","journal-title":"Am Heart J"},{"issue":"1","key":"4035_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/107327481502200106","volume":"22","author":"T Watkins","year":"2015","unstructured":"Watkins T, Surowiecka MK, McCullough J (2015) Transfusion indications for patients with cancer. Cancer Control 22(1):38\u201346. \n                    https:\/\/doi.org\/10.1177\/107327481502200106","journal-title":"Cancer Control"},{"issue":"3","key":"4035_CR38","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00520-015-2877-4","volume":"24","author":"F Lai-Tiong","year":"2016","unstructured":"Lai-Tiong F, Brami C, Dubroeucq O, Scotte F, Cure H, Jovenin N (2016) Management of anemia and iron deficiency in a cancer center in France. Support Care Cancer 24(3):1091\u20131096. \n                    https:\/\/doi.org\/10.1007\/s00520-015-2877-4","journal-title":"Support Care Cancer"},{"issue":"2","key":"4035_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00520-007-0311-2","volume":"16","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abraham I, Bokemeyer C, Ludwig H, Macdonald K, Soubeyran P, Turner M (2008) The background and methodology of the anaemia cancer treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Support Care Cancer 16(2):193\u2013200. \n                    https:\/\/doi.org\/10.1007\/s00520-007-0311-2","journal-title":"Support Care Cancer"},{"issue":"9","key":"4035_CR40","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ejca.2009.02.003","volume":"45","author":"H Ludwig","year":"2009","unstructured":"Ludwig H, Aapro M, Bokemeyer C, Macdonald K, Soubeyran P, Turner M, Albrecht T, Abraham I (2009) Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the anaemia cancer treatment (ACT) study. Eur J Cancer 45(9):1603\u20131615. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2009.02.003","journal-title":"Eur J Cancer"},{"issue":"8","key":"4035_CR41","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00520-014-2189-0","volume":"22","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, Osterborg A, Rzychon B, Mitchell D, Beguin Y (2014) A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 22(8):2197\u20132206. \n                    https:\/\/doi.org\/10.1007\/s00520-014-2189-0","journal-title":"Support Care Cancer"},{"issue":"3","key":"4035_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/jcpt.12269","volume":"40","author":"K Hollingsworth","year":"2015","unstructured":"Hollingsworth K, Romney MC, Crawford A, McAna J (2015) Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration\u2019s strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia. J Clin Pharm Ther 40(3):299\u2013303. \n                    https:\/\/doi.org\/10.1111\/jcpt.12269","journal-title":"J Clin Pharm Ther"},{"key":"4035_CR43","first-page":"1","volume":"8","author":"J-L Mouysset","year":"2016","unstructured":"Mouysset J-L, Freier B, van den Bosch J, Levache CB, Bols A, Tessen HW, Belton L, Bohac C, Terwey JH, Tonini G (2016) Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study. Care Manag Res 8:1\u201310","journal-title":"Care Manag Res"},{"issue":"9","key":"4035_CR44","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s00520-011-1318-2","volume":"20","author":"DH Henry","year":"2012","unstructured":"Henry DH, Langer CJ, McKenzie RS, Piech CT, Senbetta M, Schulman KL, Stepanski EJ (2012) Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review. Support Care Cancer 20(9):2089\u20132096. \n                    https:\/\/doi.org\/10.1007\/s00520-011-1318-2","journal-title":"Support Care Cancer"},{"key":"4035_CR45","volume":"10","author":"JL Carson","year":"2016","unstructured":"Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC (2016) Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 10:CD002042","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4035_CR46","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/asheducation-2014.1.548","volume":"2014","author":"JL Carson","year":"2014","unstructured":"Carson JL, Strair R (2014) Transfusion strategies in hematologic and nonhematologic disease. Hematology Am Soc Hematol Educ Program 2014(1):548\u2013552. \n                    https:\/\/doi.org\/10.1182\/asheducation-2014.1.548","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-4035-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-4035-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-4035-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T04:55:29Z","timestamp":1568696129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-4035-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4035"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-4035-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]},"assertion":[{"value":"29 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"James Granfortuna, Kaye Shoffner, and Stephen E. DePasquale have no financial relationships or conflicts of interest to disclose. Sejal Badre was an employee of Amgen Inc. at the time of the study and owns\/may have owned stock in Amgen Inc. Chet Bohac was an employee of Amgen Inc. at the time of the study and owns\/may have owned stock in Amgen Inc.; he is currently an employee of and owns stock in Immune Design. Cisio De Oliveira Brandao is an employee of and owns stock in Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}